Literature DB >> 20047350

Does effective management of sleep disorders reduce depressive symptoms and the risk of depression?

Dieter Riemann1.   

Abstract

The link between co-morbid insomnia and depression has been demonstrated in numerous groups. Insomnia has been associated with: (1) an increased risk of developing subsequent depression; (2) an increased duration of established depression; and (3) relapse following treatment for depression. In addition, specific insomnia symptoms, such as nocturnal awakening with difficulty resuming sleep, are more strongly associated with depression than classic symptoms of insomnia. Participants of a workshop, held at the 6th annual meeting of The International Sleep Disorders Forum: The Art of Good Sleep in 2008, evaluated whether the effective management of sleep disorders could reduce both concurrent depressive symptoms and the risk of developing subsequent depression. Following the workshop, a targeted literature review was conducted. Initial evidence demonstrated that in patients with insomnia and co-morbid depression either pharmacological treatment of insomnia or psychological treatment in the form of cognitive behavioural therapy for insomnia improved both insomnia and depressive symptoms. Although these appeared to be promising treatment strategies, however, of the 27 identified treatment studies, only one large well-designed randomized controlled trial comparing the efficacy of eszopiclone plus fluoxetine with placebo plus fluoxetine demonstrated unequivocal evidence that improvements in insomnia symptoms conferred additive benefits on depressive outcomes. In addition, it was unclear whether any differences exist in efficacy between sedating versus non-sedating pharmacotherapies for insomnia in this patient group. Further studies of sufficient sample size and duration are needed to evaluate combinations of pharmacological (either sedating or non-sedating) and psychological interventions in co-morbid insomnia and depression. This article reviews the level of evidence, recommendations and areas of particular interest for further study and discussion arising from this workshop.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20047350     DOI: 10.2165/11531130-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  107 in total

1.  Residual symptoms in depressed patients who respond acutely to fluoxetine.

Authors:  A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

2.  Evaluation of sleep architecture and cyclic alternating pattern rates in depressed insomniac patients treated with nefazodone hydrochloride.

Authors:  M B Scharf; M McDannold; N Zaretsky; O Spinner; R Stover; D V Berkowitz; C Conrad
Journal:  Am J Ther       Date:  1999-03       Impact factor: 2.688

3.  A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.

Authors:  R Armitage; K Yonkers; D Cole; A J Rush
Journal:  J Clin Psychopharmacol       Date:  1997-06       Impact factor: 3.153

Review 4.  Insomnia and comorbid psychiatric disorders.

Authors:  Dieter Riemann
Journal:  Sleep Med       Date:  2007-12       Impact factor: 3.492

5.  Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study.

Authors:  F M Jacobsen
Journal:  J Clin Psychiatry       Date:  1990-07       Impact factor: 4.384

6.  Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?

Authors:  Alexandre Y Dombrovski; Jill M Cyranowski; Benoit H Mulsant; Patricia R Houck; Daniel J Buysse; Carmen Andreescu; Michael E Thase; Alan G Mallinger; Ellen Frank
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

7.  Difficulty in resuming or inability to resume sleep and the links to daytime impairment: definition, prevalence and comorbidity.

Authors:  Maurice M Ohayon
Journal:  J Psychiatr Res       Date:  2009-03-03       Impact factor: 4.791

8.  Population study on the prevalence of insomnia and insomnia-related factors among Japanese women.

Authors:  Tomoyuki Kawada; Sasazawa Yosiaki; Kiryu Yasuo; Shosuke Suzuki
Journal:  Sleep Med       Date:  2003-11       Impact factor: 3.492

9.  Comorbidity of mental and insomnia disorders in the general population.

Authors:  M M Ohayon; M Caulet; P Lemoine
Journal:  Compr Psychiatry       Date:  1998 Jul-Aug       Impact factor: 3.735

10.  Risk markers for depression in adolescents: sleep and HPA measures.

Authors:  Uma Rao; Constance L Hammen; Russell E Poland
Journal:  Neuropsychopharmacology       Date:  2009-03-04       Impact factor: 7.853

View more
  12 in total

1.  Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey.

Authors:  Grant H Louie; Maria G Tektonidou; Alberto J Caban-Martinez; Michael M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-02       Impact factor: 4.794

2.  Internet treatment addressing either insomnia or depression, for patients with both diagnoses: a randomized trial.

Authors:  Kerstin Blom; Susanna Jernelöv; Martin Kraepelien; Malin Olséni Bergdahl; Kristina Jungmarker; Linda Ankartjärn; Nils Lindefors; Viktor Kaldo
Journal:  Sleep       Date:  2015-02-01       Impact factor: 5.849

Review 3.  Sleep, insomnia, and depression.

Authors:  Dieter Riemann; Lukas B Krone; Katharina Wulff; Christoph Nissen
Journal:  Neuropsychopharmacology       Date:  2019-05-09       Impact factor: 7.853

4.  CBT for insomnia in patients with high and low depressive symptom severity: adherence and clinical outcomes.

Authors:  Rachel Manber; Rebecca A Bernert; Sooyeon Suh; Sara Nowakowski; Allison T Siebern; Jason C Ong
Journal:  J Clin Sleep Med       Date:  2011-12-15       Impact factor: 4.062

5.  Sleep disturbances and nocturnal symptoms: relationships with quality of life in a population-based sample of women with interstitial cystitis/bladder pain syndrome.

Authors:  Wendy M Troxel; Marika Booth; Daniel J Buysse; Marc N Elliott; Anne M Suskind; J Quentin Clemens; Sandra H Berry
Journal:  J Clin Sleep Med       Date:  2014-12-15       Impact factor: 4.062

6.  [Insomnia--state of the science].

Authors:  D Riemann; C Baglioni; B Feige; K Spiegelhalder
Journal:  Nervenarzt       Date:  2014-01       Impact factor: 1.214

Review 7.  Cognitive-behavioral therapy for the management of insomnia comorbid with mental disorders.

Authors:  María Montserrat Sánchez-Ortuño; Jack D Edinger
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

8.  Energetic and cell membrane metabolic products in patients with primary insomnia: a 31-phosphorus magnetic resonance spectroscopy study at 4 tesla.

Authors:  David G Harper; David T Plante; J Eric Jensen; Caitlin Ravichandran; Orfeu M Buxton; Kathleen L Benson; Shawn P O'Connor; Perry F Renshaw; John W Winkelman
Journal:  Sleep       Date:  2013-04-01       Impact factor: 5.849

9.  Clinical implications of the causal relationship between insomnia and depression: how individually tailored treatment of sleeping difficulties could prevent the onset of depression.

Authors:  Chiara Baglioni; Kai Spiegelhalder; Christoph Nissen; Dieter Riemann
Journal:  EPMA J       Date:  2011-04-28       Impact factor: 6.543

10.  Impaired Recognition of Facially Expressed Emotions in Different Groups of Patients with Sleep Disorders.

Authors:  Tatjana Crönlein; Berthold Langguth; Peter Eichhammer; Volker Busch
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.